An International Learning Collaborative Phase 2 Trial for Haploidentical Bone Marrow Transplant in Sickle Cell Disease (2024)

Table of Contents
Credits Available You Are Eligible For Target Audience and Goal Statement Disclosures Faculty Adetola A. Kassim, MD, MS Josu de la Fuente, MD, PhD Erfan Nur, MD, PhD Karina L. Wilkerson, APN, FNP-C Ali D. Alahmari, MD Adriana Seber, MD, MS Carmem M.S. Bonfim, MD, PhD Belinda Pinto Simões, MD, PhD Mohsen Alzahrani, MD Michael J. Eckrich, MD Biljana Horn, MD Rabi Hanna, MD Nathalie Dhedin, MD Hemalatha G. Rangarajan, MD Roseane Vasconcelos Gouveia, MD Fahad Almohareb, MD Mahmoud Aljurf, MD, MPH Mohammed Essa, MBBS, FRCPC Bader Alahmari, MBBS, MSCI Katie S. Gatwood, PharmD James A. Connelly, MD Elisabeth Dovern, MD Mark Rodeghier, PhD Michael R. DeBaun, MD, MPH CME Author Laurie Barclay, MD Editor Robert Zeiser, MD Compliance Reviewer Amanda Jett, PharmD, BCACP Accreditation Statements For Physicians Instructions for Participation and Credit

  • An International Learning Collaborative Phase 2 Trial for Haploidentical Bone Marrow Transplant in Sickle Cell Disease (1)

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points
    • An International Learning Collaborative Phase 2 Trial for Haploidentical Bone Marrow Transplant in Sickle Cell Disease (2)

Target Audience and Goal Statement

This activity is intended for hematologists, oncologists, internists, pediatricians, and other clinicians caring for patients with sickle cell disease (SCD).

The goal of this activity is for learners to be better able to describe whether non--myeloablative-related haploidentical bone marrow transplantation (haplo-BMT) with thiotepa and posttransplant cyclophosphamide (PTCy) achieves 2-year event-free survival (EFS [ie, no graft failure or death]) of 80% or more, based on an international, multicenter, phase 2 clinical trial with 70 evaluable participants (median age, 19.1 years) based on the conditioning protocol.

Upon completion of this activity, participants will:

  • Describe event-free survival (EFS) and overall survival (OS) in patients with sickle cell disease (SCD) treated with nonmyeloablative related haploidentical bone marrow transplantation (haplo-BMT) with thiotepa and posttransplant cyclophosphamide (PTCy), based on an international, multicenter, phase 2 clinical trial with 70 evaluable participants
  • Determine graft-versus-host disease (GVHD) rate, infections, and associated factors in patients with SCD treated with nonmyeloablative-related haplo-BMT with thiotepa and PTCy, based on an international multicenter phase 2 clinical trial with 70 evaluable participants
  • Identify clinical implications of EFS, OS, and GVHD in patients with SCD treated with nonmyeloablative-related haplo-BMT with thiotepa and PTCy, based on an international multicenter phase 2 clinical trial with 70 evaluable participants

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

  • Adetola A. Kassim, MD, MS

    Department of Medicine
    Division of Hematology/Oncology
    Vanderbilt-Meharry Sickle Cell Disease Center of Excellence
    Vanderbilt University School of Medicine
    Nashville, Tennessee

  • Erfan Nur, MD, PhD

    Department of Hematology
    Amsterdam University Medical Centers
    University of Amsterdam
    Department of Blood Cell Research
    Sanquin Research
    Amsterdam, the Netherlands

  • Karina L. Wilkerson, APN, FNP-C

    Department of Medicine
    Division of Hematology/Oncology
    Vanderbilt-Meharry Sickle Cell Disease Center of Excellence
    Vanderbilt University School of Medicine
    Nashville, Tennessee

  • Ali D. Alahmari, MD

    King Faisal Specialist Hospital
    Riyadh, Saudi Arabia

  • Adriana Seber, MD, MS

    Pediatric Hematopoietic Cell Transplantation
    Hospital Samaritano Higienopolis–Americas
    Pediatric Hematopoietic Cell Transplantation
    Instituto de Oncologia Pediatrica–Graacc/Unifesp
    São Paulo, Brazil

  • Carmem M.S. Bonfim, MD, PhD

    Pediatric Bone Marrow Transplantation Program
    Hospital Pequeno Príncipe/Instituto de Pesquisa Pele Pequeno Principe
    Curitiba, Brazil

  • Belinda Pinto Simões, MD, PhD

    Departments of Medical Imaging and Hematology/Clinical Oncology
    Ribeirão Preto Medical School
    University of São Paulo
    São Paulo, Brazil

  • Mohsen Alzahrani, MD

    King Abdulaziz Medical City
    Ministry of National Guard—Health Affairs
    King Abdullah International Medical Research Center
    King Saud Bin Abdulaziz University for Health Sciences
    Riyadh, Saudi Arabia

  • Michael J. Eckrich, MD

    Pediatric Transplant and Cellular Therapy
    Wake Forest University School of Medicine
    Atrium Health Levine Children's Hospital
    Charlotte, North Carolina

  • Biljana Horn, MD

    Pediatric Bone Marrow Transplant and Cell Therapy Program
    University of Florida
    Gainesville, Florida

  • Rabi Hanna, MD

    Pediatric Hematology Oncology and Blood and Marrow Transplantation
    Cleveland Clinic
    Cleveland, Ohio

  • Nathalie Dhedin, MD

    Hematology Adolescents and Young Adults
    Saint-Louis Hôspital
    Paris, France

  • Hemalatha G. Rangarajan, MD

    Department of Pediatric Hematology
    Oncology, Blood and Marrow Transplant
    Nationwide Children’s Hospital
    Columbus, Ohio

  • Roseane Vasconcelos Gouveia, MD

    Pediatric Hematopoietic Cell Transplantation
    Hospital Samaritano Higienopolis–Americas
    Pediatric Hematopoietic Cell Transplantation
    Instituto de Oncologia Pediatrica–Graacc/Unifesp
    São Paulo, Brazil

  • Fahad Almohareb, MD

    King Faisal Specialist Hospital
    Riyadh, Saudi Arabia

  • Mahmoud Aljurf, MD, MPH

    King Faisal Specialist Hospital
    Riyadh, Saudi Arabia

  • Mohammed Essa, MBBS, FRCPC

    King Abdulaziz Medical City
    Ministry of National Guard—Health Affairs
    King Abdullah International Medical Research Center
    King Saud Bin Abdulaziz University for Health Sciences
    Riyadh, Saudi Arabia

  • Katie S. Gatwood, PharmD

    Department of Pharmaceutical Services
    Vanderbilt University Medical Center
    Nashville, Tennessee

  • James A. Connelly, MD

    Department of Pediatrics, Hematology/Oncology
    Vanderbilt University School of Medicine
    Nashville, Tennessee

  • Elisabeth Dovern, MD

    Department of Paediatrics
    St Mary’s Hospital
    Imperial College
    London, United Kingdom

  • Mark Rodeghier, PhD

    Rodeghier Consultants
    Chicago, Illinois

  • Michael R. DeBaun, MD, MPH

    Vanderbilt-Meharry Sickle Cell Disease Center of Excellence
    Vanderbilt University School of Medicine
    Nashville, Tennessee

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer
    Medscape, LLC

    Disclosures

    Laurie Barclay, MD, has no relevant financial relationships.

Editor

  • Robert Zeiser, MD

    Associate Editor, Blood

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Accreditation Statements

An International Learning Collaborative Phase 2 Trial for Haploidentical Bone Marrow Transplant in Sickle Cell Disease (3)


An International Learning Collaborative Phase 2 Trial for Haploidentical Bone Marrow Transplant in Sickle Cell Disease (4)

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and the American Society of Hematology. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [emailprotected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

An International Learning Collaborative Phase 2 Trial for Haploidentical Bone Marrow Transplant in Sickle Cell Disease (2024)
Top Articles
Luigi’s Mansion 2 HD Review - IGN
12 Best Sites to Download Nintendo Switch ROMs
Scoreboard: PRCA rodeo results
Sweet Payouts and Treats Draw Top Cowboys to Strawberry Days
Bfri Forum
Breckie Hill Skateboard Leak: Unveiling the Truth
shreveport pickups and trucks for sale - craigslist
When did Black voters shift to Democrats? Earlier than you might think.
The UPS Store | Ship & Print Here > 931 S Main St
The UPS Store | Ship & Print Here > 4026 Wards Rd
Revelation 8:6 - The First Four Trumpets
What Will Happen When The Seven Trumpets of Revelation Are Blown?
Latest Posts
Lourdes Patient Portal Login Official @ lourdes.com
Any homebrew using USB to install large xci games to fat32 SD?
Article information

Author: Twana Towne Ret

Last Updated:

Views: 6113

Rating: 4.3 / 5 (44 voted)

Reviews: 91% of readers found this page helpful

Author information

Name: Twana Towne Ret

Birthday: 1994-03-19

Address: Apt. 990 97439 Corwin Motorway, Port Eliseoburgh, NM 99144-2618

Phone: +5958753152963

Job: National Specialist

Hobby: Kayaking, Photography, Skydiving, Embroidery, Leather crafting, Orienteering, Cooking

Introduction: My name is Twana Towne Ret, I am a famous, talented, joyous, perfect, powerful, inquisitive, lovely person who loves writing and wants to share my knowledge and understanding with you.